Gut barrier / inflammation
Larazotide
An orally administered octapeptide that acts as a tight-junction regulator (zonulin antagonist) to reduce intestinal permeability. The most clinically advanced of the 'leaky gut' peptides, studied in controlled celiac-disease trials, though it has not gained approval.
Common doses
| Indication | Route | Dose | Duration | Evidence |
|---|---|---|---|---|
| Celiac disease (persistent symptoms despite gluten-free diet) — clinical trials | Oral | Studied around 0.5 mg three times daily in trials | Trial-defined | Tier 3 |
| Intestinal permeability / 'leaky gut' (off-label, experimental) | Oral | No established consumer dose | Experimental | Tier 5 |
Ask about Larazotide
Get an answer from our reviewed articles and community reports, with links to the sources. Not medical advice.
Limitations · Who should NOT use this
Despite being the most studied gut-barrier peptide, larazotide is not approved: a phase 2b trial showed promise for celiac symptoms, but a later pivotal phase 3 trial did not meet its primary endpoint, and development has been uncertain. 'Leaky gut' as a standalone consumer indication is not well-defined clinically. Trial dosing does not translate directly to self-directed gray-market use. Best understood as an investigational adjunct studied in a specific disease, not a validated general gut-health supplement.
Regulatory notes
Not FDA-approved. The most clinically advanced gut-barrier peptide — studied in randomized controlled trials for celiac disease (including a phase 2b trial), though a pivotal phase 3 did not meet its primary endpoint. Investigational; not available as an approved product.
Sources
- Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 2015;148(7):1311-1319.
- Khaleghi S, et al. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol 2016;9(1):37-49.
- Paterson BM, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of AT-1001 in celiac disease. Aliment Pharmacol Ther 2007.
Community signal — Larazotide
Recent posts and videos mentioning Larazotide from the cron-ingested Reddit + X pipelines and the curated /experts directory. Not endorsement — directional context only.
- r/Peptides· u/Ok_Number_6710 · 10d ago
Larazotide Success Stories? Especially When Combined with BPC-157 + KPV
Larazotide Success Stories? Especially When Combined with BPC-157 + KPV
- r/Peptides· u/Ok_Number_6710 · 14d ago
Looking for Legit BPC-157, KPV & Larazotide in Tijuana After Endoscopy Results
Looking for Legit BPC-157, KPV & Larazotide in Tijuana After Endoscopy Results
No X posts mentioning Larazotide in our index yet — the X cron pulls from curated accounts every six hours.
No curated experts have Larazotide tagged in their peptideAreas yet.
No YouTube videos mentioning Larazotide in our index yet. The YouTube RSS cron pulls every 6 hours.
Community experiences
0 approved · moderatedFirst-hand accounts from readers who've used Larazotide. These are personal anecdotes, not clinical evidence or medical advice — every post is reviewed before it appears.
Community Notes
0 approved · moderated
Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.
No approved notes yet.
Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.
Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.